5-Amino-1MQ: The 2026 Buyer's Guide to NNMT Inhibition for Metabolic Health

Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC. Last reviewed May 28, 2026.

The short answer

5-Amino-1MQ (full name: 5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). NNMT is overexpressed in fat cells in patients with obesity, metabolic syndrome, and insulin resistance. By blocking NNMT, 5-Amino-1MQ raises intracellular NAD+ in adipose tissue, which restores mitochondrial function and increases metabolic rate.

What it does well: supports fat metabolism, raises intracellular NAD+ in adipose, complements GLP-1 protocols, and generally produces few side effects.

What it does not do: suppress appetite the way semaglutide or tirzepatide do, produce rapid weight loss as a standalone agent, or replace caloric deficit.

The honest evidence note: the preclinical animal data is strong and consistent. Human clinical trial data is still early. Patients should view 5-Amino-1MQ as a metabolic support agent with a solid mechanistic rationale and a limited human safety database compared to FDA-approved weight loss drugs.

RxPepsDirect prices 5-Amino-1MQ at $80 per 25mg vial through Optimal Balance Pharmacy. Standard protocol is 1mg daily, so one vial covers roughly four weeks.

What is 5-Amino-1MQ?

5-Amino-1MQ is a small molecule, not a peptide. The full chemical name is 5-amino-1-methylquinolinium iodide. It is a derivative of quinoline (a heterocyclic aromatic ring system) with an amino group at the 5-position and a methyl group on the nitrogen.

The compound was developed as a research tool to inhibit the enzyme nicotinamide N-methyltransferase (NNMT). NNMT methylates nicotinamide (the precursor to NAD+) and removes it from the cell's available NAD+ salvage pool. When NNMT activity is high, less nicotinamide is available to recycle into NAD+, and intracellular NAD+ falls.

Researchers noticed that NNMT was highly overexpressed in the adipose tissue of obese mice and humans. Genetic knockdown of NNMT in mice produced striking metabolic improvements: increased NAD+, increased fatty acid oxidation, reduced fat mass on a high-fat diet, and improved insulin sensitivity. 5-Amino-1MQ was developed to reproduce that knockdown effect pharmacologically.

5-Amino-1MQ is included in our weight loss catalog because it is commonly stacked with peptide protocols for metabolic goals, but it is not technically a peptide. The full 5-Amino-1MQ product page has current pricing and the prescription pathway.

How NNMT inhibition works

NAD+ is a coenzyme essential to virtually all energy metabolism. Mitochondrial ATP production, fatty acid oxidation, glucose handling, and sirtuin-mediated cellular repair all depend on adequate intracellular NAD+. NAD+ levels fall with age and with metabolic stress.

The body maintains NAD+ through a salvage pathway that recycles nicotinamide back into NAD+. NNMT competes with that salvage pathway. NNMT takes nicotinamide and adds a methyl group, producing 1-methylnicotinamide. The methylated product cannot be recycled into NAD+ and is excreted in urine.

When NNMT is overexpressed (as it is in obese adipose tissue), the cell methylates and exports more nicotinamide than it should, and the local NAD+ pool drops. The mitochondria become inefficient, fatty acid oxidation slows, and the fat cell becomes metabolically dysfunctional.

5-Amino-1MQ binds the active site of NNMT and prevents that methylation. Nicotinamide stays in the salvage pool and gets recycled into NAD+. Intracellular NAD+ rises. Mitochondrial function recovers. Fatty acid oxidation increases. The fat cell becomes more metabolically active.

This is a fundamentally different mechanism from GLP-1 agonists or GH secretagogues. GLP-1 agonists work at the brain and gut to reduce intake. GH secretagogues work at the pituitary to mobilize fat through GH/IGF-1. 5-Amino-1MQ works at the fat cell itself by restoring the NAD+ that the cell needs to burn fuel. See the full NAD+ supplement guide for context on why NAD+ matters.

What 5-Amino-1MQ actually does

Based on preclinical and early human data, 5-Amino-1MQ supports:

• Increased NAD+ in adipose tissue: the primary, most reliably reproduced effect across animal models
• Increased mitochondrial oxidation of fatty acids: the downstream metabolic consequence of restored NAD+
• Reduced fat mass on a high-fat diet in obese mouse models: roughly 7 to 8 percent reduction over 11 days at therapeutic doses in published rodent studies
• Improved insulin sensitivity: reduced fasting glucose and improved oral glucose tolerance in mouse models
• No reduction in lean muscle mass: the metabolic improvement is targeted at adipose, not skeletal muscle
• Increased energy expenditure: measurable increases in metabolic rate in animal studies

In the clinic, patients typically report subjective effects on energy and body composition at 4 to 8 weeks. Measurable body composition changes usually require 8 to 12 weeks of consistent dosing.

The honest evidence picture

We will not oversell the data here. The clinical situation for 5-Amino-1MQ in 2026 is:

Strong preclinical evidence. Multiple peer-reviewed studies in obese mouse models show consistent metabolic improvements: reduced fat mass, improved glucose handling, increased NAD+, reduced inflammation in adipose. Mechanistic studies in human adipose tissue confirm NNMT is overexpressed in obesity. The biology is well-supported.

Limited human clinical trial data. Human RCTs with 5-Amino-1MQ specifically are still in early phases. Clinicians prescribing 5-Amino-1MQ in 2026 are working from mechanism, animal data, and patient-reported outcomes rather than from large randomized trials.

What this means practically. If you want a weight-loss agent with large randomized trials behind it, semaglutide and tirzepatide are the right choice. If you want a metabolic support agent with strong mechanistic logic, a clean side-effect profile in early human use, and complementary action to your existing protocol, 5-Amino-1MQ fits that niche. Most 5-Amino-1MQ patients use it as a stack component rather than a monotherapy.

5-Amino-1MQ vs GLP-1 agonists

The comparison most patients ask about: how does 5-Amino-1MQ stack up against semaglutide or tirzepatide?

The honest summary: GLP-1 agonists are the right primary tool for patients seeking meaningful weight loss. 5-Amino-1MQ is a mechanism-based metabolic adjunct that fits patients who want to support cellular metabolism without appetite suppression, or who want to add a complementary mechanism to a GLP-1 protocol.

Dosing protocol

• Concentration: 5mg/mL (25mg total in a 5mL vial)
• Dose: 1mg per injection (20 units, or 0.2mL)
• Frequency: Daily, ideally morning or pre-workout to align with peak metabolic activity
• Route: Subcutaneous injection (abdomen or thigh)
• Duration: 8 to 12 weeks per cycle, may be extended based on provider review
• Vial yield: 25 doses per vial at 1mg daily (~4 weeks per vial)
• Beyond Use Date: 90 days from compounding per USP 797 after reconstitution

Optimal Balance Pharmacy ships 5-Amino-1MQ pre-reconstituted in a reusable cooled travel case via FedEx overnight. No mixing required.

Side effects and contraindications

5-Amino-1MQ has been generally well-tolerated in early human clinical use. The most commonly reported issues are:

• Injection-site reactions: mild redness or itching at the injection site, typically resolves within 24 hours
• Mild headache: occasional in the first week, usually self-limiting
• Mild nausea: uncommon, more likely if injected on an empty stomach in sensitive patients
• Transient energy shifts: some patients report a mild energy boost in the first 2 to 4 weeks

Long-term safety note. The human safety database for 5-Amino-1MQ is smaller than for FDA-approved drugs. Patients should view this as part of the calculus: a strong mechanistic rationale and good preclinical safety profile, with a smaller clinical track record. RxPepsDirect providers screen for contraindications on intake.

Contraindications:

• Pregnancy or breastfeeding
• Active malignancy or recent cancer history
• Active liver disease or significantly elevated liver enzymes
• Concurrent use of metabolic medications without provider review

Cost and comparison

5-Amino-1MQ is dispensed by Optimal Balance Pharmacy at 503A wholesale through RxPepsDirect.

Plus the one-time $39 RxPepsDirect provider review. No subscription, no markup, no membership.

How to get a prescription

5-Amino-1MQ is a prescription product, not a supplement. Here is the pathway through RxPepsDirect:

1. Add 5-Amino-1MQ to your protocol on the 5-Amino-1MQ product page. You can stack up to three SKUs per provider review.
2. Complete the medical intake. Pay the $39 provider review fee.
3. A licensed RxPepsDirect provider (Dr. Jonathan Snipes, MD or Kim Callender, FNP-BC) reviews your intake within 24 to 48 hours and approves the appropriate protocol for your goals.
4. The prescription is sent to Optimal Balance Pharmacy. They compound the product, ship pre-reconstituted via FedEx overnight in a reusable cooled travel case.
5. Refills are per vial, no auto-billing. Re-request when you need the next one. Most patients reorder every 4 weeks at standard dosing.

Related guides

• NAD+ supplements 2026 buyer's guide covers why NAD+ matters and the supplement landscape
• The peptide therapy pillar guide for context on how peptide-class protocols fit together
• NAD+ injections online for the prescription NAD+ pathway
• Compounded peptides vs research-grade explains why a prescription pathway matters